Mitochondrial toxin inhibition of [(3)H]dopamine uptake into rat striatal synaptosomes.

Biochem Pharmacol

Department of Neurology, Kentucky Clinic, Room L-445, University of Kentucky Medical Center, Lexington, KY 40536, USA.

Published: April 2002

Administration of the mitochondrial inhibitors malonate and 3-nitropropionic acid (3-NP) to rats provides useful models of Huntington's disease. Exposure to these inhibitors has been shown to result in increased extracellular concentrations of striatal dopamine (DA), which is neurotoxic at high concentrations. The cause of this increase is unknown. The purpose of this study was to determine whether mitochondrial inhibition alters dopamine transporter (DAT) function. Striatal synaptosomes were incubated in the presence of several structurally unrelated inhibitors of mitochondrial Complexes I, II, and IV, and [(3)H]DA uptake was measured. Although all of the toxins inhibited [(3)H]DA uptake, there was a large variation in their inhibitory potencies, the rank order being rotenone>>cyanide>azide>3-NP>>malonate. Examination of the kinetic parameters of [(3)H]DA uptake revealed that inhibition was due to a reduction in maximum velocity (V(max)), with no change in affinity (K(m)). The addition of either ATP or of ADP plus P(i) to synaptosomes treated with 3-NP, or of the reactive oxygen species spin trap alpha-phenyl-N-tert-butyl nitrone to synaptosomes exposed to either malonate or cyanide failed to prevent mitochondrial toxin-induced inhibition of DAT function. The lack of effect of high energy substrates or of a free radical scavenger suggests that the mechanism by which extracellular DA is increased by several mitochondrial toxins involves factors other than mitochondrial ATP production or oxidative stress. Taken together, the results suggest that one mechanism whereby mitochondrial toxins increase extracellular concentrations of DA is via interaction with the DAT at a site other than the substrate site, i.e. noncompetitive inhibition of the DAT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(02)00910-3DOI Listing

Publication Analysis

Top Keywords

[3h]da uptake
12
mitochondrial
8
striatal synaptosomes
8
extracellular concentrations
8
dat function
8
inhibition dat
8
mitochondrial toxins
8
inhibition
5
mitochondrial toxin
4
toxin inhibition
4

Similar Publications

Article Synopsis
  • Parkinson's disease (PD) is rapidly increasing globally, especially in industrialized regions, indicating potential environmental influences, specifically from pollutants like dieldrin, a pesticide.
  • Research on mice reveals that exposure to dieldrin during development makes them more vulnerable to neuron damage and motor function deficits when exposed to α-synuclein, a protein linked to PD.
  • The study shows that while dieldrin exposure increases dopamine release in certain brain areas affected by α-synuclein, it doesn't change VMAT2 activity, suggesting that early exposure to dieldrin may heighten the brain's response to neurodegeneration without obvious signs of damage.
View Article and Find Full Text PDF

The G2019S mutation in leucine rich-repeat kinase 2 (LRRK2) is a major cause of familial Parkinson's disease. We previously reported that G2019S knock-in mice manifest dopamine transporter dysfunction and phosphoSerine129 α-synuclein (pSer129 α-syn) immunoreactivity elevation at 12 months of age, which might represent pathological events leading to neuronal degeneration. Here, the time-dependence of these changes was monitored in the striatum of 6, 9, 12, 18 and 23-month-old G2019S KI mice and wild-type controls using DA uptake assay, Western analysis and immunohistochemistry.

View Article and Find Full Text PDF

Target-directed evolution of novel modulators of the dopamine transporter in Lobelia cardinalis hairy root cultures.

J Biotechnol

December 2021

Naprogenix™, UK-AsTeCC, 145 Graham Avenue, Lexington, KY 40506-0286, USA; College of Medicine, Department of Neurology, University of Kentucky Chandler Medical Center, 740 S. Limestone, Lexington, KY 40536-0298, USA; College of Arts and Sciences, Department of Psychology, University of Kentucky, Kastle Hall, Lexington, KY 40506-0044, USA.

The dopamine transporter (DAT) is targeted in substance use disorders (SUDs), and "non-classical"" DAT inhibitors with low abuse potential are therapeutic candidates. Lobinaline, from Lobelia cardinalis, is an atypical DAT inhibitor lead. Chemical synthesis of lobinaline is challenging; thus, "target-directed evolution" was used for lead optimization.

View Article and Find Full Text PDF

The aim of this study was to demonstrate the effects of atrial natriuretic peptide (ANP) on organic cation transporters (OCTs) expression and activity, and its consequences on dopamine urinary levels, Na+, K+-ATPase activity and renal function. Male Sprague Dawley rats were infused with isotonic saline solution during 120 minutes and randomized in nine different groups: control, pargyline plus tolcapone (P+T), ANP, dopamine (DA), D-22, DA+D-22, ANP+D-22, ANP+DA and ANP+DA+D-22. Renal functional parameters were determined and urinary dopamine concentration was quantified by HPLC.

View Article and Find Full Text PDF

Original mechanisms of antipsychotic action by the indole alkaloid alstonine (Picralima nitida).

Phytomedicine

January 2015

Laboratório de Etnofarmacologia, Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Avenida Sarmento Leite, 500, 90050-170, Porto Alegre, RS, Brazil ; Programa de Pós-graduação em Ciências Biológicas: Bioquímica Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Avenida Sarmento Leite, 500, 90050-170, Porto Alegre, RS, Brazil.

Alstonine is the major component of plant based remedies that traditional psychiatrists use in Nigeria. Alstonine is an indole alkaloid that has an antipsychotic experimental profile comparable with that of clozapine and is compatible with the alleged effects in mental patients. Representing a desirable innovation in the pharmacodynamics of antipsychotic medications, the evidence indicates that alstonine does not bind to D2 dopamine receptors (D2R) and differentially regulates dopamine in the cortical and limbic areas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!